The bacterium Clostridioides difficile is named “difficult” for a reason. Originally it was hard to grow in the lab, and now ...

Ten years after first collecting an FDA approval, it’s time for version number two. | Cologuard Plus represents the next ...

Mosnodenvir is designed to block interactions between two dengue virus proteins. The vaccine survived J&J’s decision last ...

Prothena, a company focused on neurodegenerative diseases, is shaking up its C-suite. The exec moves were announced just a ...

A minority of patients taking Ultragenyx Pharmaceutical’s Wilson disease gene therapy UX701 have come off standard-of-care ...

Against the backdrop of a Cas9 patent battle that refuses to die, Editas Medicine is cashing in a chunk of the licensing ...

Precision medicines biotech Relay Therapeutics is shedding about 10% of its workforce in efforts to streamline the ...

One of those companies, a contract research organization focused on genetic medicines called Franklin Biolabs, officially ...

Kurma plans to raise a total of 250 million euros ($276 million) for the fund, dubbed Biofund IV, which would make it the ...

Big Pharma is investing heavily in AI to slash development timelines and foster innovation. | Big Pharma is investing heavily ...

The digital pathology developer Proscia is launching an artificial intelligence toolkit for life science researchers, ...

Pentixapharm has brought in almost 20 million euros ($22 million) from an IPO, with the German biotech earmarking the ...